Scientific Publications

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Publication TypeJournal Article
AuthorsPaez, JG, Jänne PA, Lee JC, Tracy S., Greulich H., Gabriel S., Herman P., Kaye FJ, Lindeman N., Boggon TJ, Naoki K., Sasaki H., Fujii Y., Eck MJ, Sellers WR, Johnson B. E., and Meyerson M.
AbstractReceptor tyrosine kinase genes were sequenced in non-small cell lung cancer (NSCLC) and matched normal tissue. Somatic mutations of the epidermal growth factor receptor gene EGFR were found in 15of 58 unselected tumors from Japan and 1 of 61 from the United States. Treatment with the EGFR kinase inhibitor gefitinib (Iressa) causes tumor regression in some patients with NSCLC, more frequently in Japan. EGFR mutations were found in additional lung cancer samples from U.S. patients who responded to gefitinib therapy and in a lung adenocarcinoma cell line that was hypersensitive to growth inhibition by gefitinib, but not in gefitinib-insensitive tumors or cell lines. These results suggest that EGFR mutations may predict sensitivity to gefitinib.
Year of Publication2004
JournalScience (New York, N.Y.)
Volume304
Issue5676
Pages1497-500
Date Published (YYYY/MM/DD)2004/06/04
ISSN Number0036-8075
DOI10.1126/science.1099314
PubMedhttp://www.ncbi.nlm.nih.gov/pubmed/15118125?dopt=Abstract